CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub

New lab to specialize in oncology research, as well as bioprinted lung and heart tissue models

CELLINK, the Gothenburg-based creator of one of the world’s first universal bioinks and a leading bioprinter developer and provider, is setting up a new lab that will enable the company to develop better kidney, heart, liver and lung tissue models for use in pharmaceutical development.


Located in the BioVentureHub, at the heart of AstraZeneca’s R&D Gothenburg site, the new lab will be staffed by a team of four scientists and researchers. They will focus on developing opportunities for customers and partners to bioprint using any type of cells relevant to the targeted applications.


The BioVentureHub continues to grow. With CELLINK onboard, and after 8 new companies joined in 2017, there are currently 25 companies and 1 academic group in the BioVentureHub.


Erik Gatenholm, (co-founder and CEO, CELLINK) “We are very happy to establish an R&D lab in AstraZeneca’s BioVentureHub. It gives us a unique opportunity to collocate with, and tap into, the power of AstraZeneca’s world-class scientists and facilities, as well as with the other exciting life science companies in the hub. Surrounded by experts in cardiovascular, metabolic, respiratory and oncology diseases, it’s a truly inspiring environment in which to develop our future offering of bioprinting technologies.”


Magnus Björsne, (CEO, AstraZeneca BioVentureHub) “CELLINK is developing exciting 3D bioprinting technologies that are enabling new ways to study biological systems and develop better treatments. Delivering on our ambition to facilitate interactions between drug, device, diagnostic and digital health companies, Erik and the CELLINK team will undoubtedly add significant value to the innovation experiment we are building here at the BioVentureHub.”


More News